Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29339279 | 0.80 | GAA (0.50) | LMNAKMT2AAOC3ALDH1A1HDAC8 | |
| SCHEMBL20088438 | 0.80 | TACR1 (0.49) | AOC3ALDH1A1CARM1 | |
| SCHEMBL1274028 | 0.78 | TACR1 (0.50) | LMNAAOC3ALDH1A1HTT | |
| SCHEMBL18251695 | 0.77 | ERCC1 (0.50) | LMNAKMT2ARPS6KB1HPGDMEN1 | |
| SCHEMBL14679434 | 0.75 | AOC3 (0.65) | LMNAAOC3CA1CA2ALDH1A1 | |
| SCHEMBL10296152 | 0.75 | HPGD (0.40) | LMNAKMT2ARPS6KB1CA1CA2 | |
| SCHEMBL16020301 | 0.74 | CYP2C9 (0.47) | LMNAAOC3CA1CA2ALDH1A1 | |
| SCHEMBL1274285 | 0.74 | LMNA (0.68) | LMNAKMT2ACA1CA2ALDH1A1 | |
| SCHEMBL18235894 | 0.74 | CA1 (0.62) | LMNAKMT2ACA1CA2ALDH1A1 | |
| SCHEMBL16020324 | 0.74 | GRM2 (0.43) | RPS6KB1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | LMNA 4198/4885KMT2A 2165/4885AOC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.